

The Natural History of Untreated "Prostatism"

British Journal of Urology

53, 613-616

DOI: [10.1111/j.1464-410x.1981.tb03273.x](https://doi.org/10.1111/j.1464-410x.1981.tb03273.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prostatism: Clinical, radiological, and urodynamic aspects. <i>Neurourology and Urodynamics</i> , 1982, 1, 241-293.	0.8	73
2	Predictive value of low maximum flow rate in benign prostatic hyperplasia. <i>Urology</i> , 1986, 27, 569-573.	0.5	21
3	A Double-Blind Trial of the Effect of Beta-Sitosteryl Glucoside (WA184) in the Treatment of Benign Prostatic Hyperplasia. <i>European Urology</i> , 1986, 12, 187-189.	0.9	27
4	The Present Role of Alpha-Adrenergic Blockers in the Treatment of Benign Prostatic Hypertrophy. <i>Journal of Urology</i> , 1986, 136, 1-4.	0.2	270
5	Clinical Evaluation of Patients with Prostatic Obstruction: Correlation of Flow Rates With Voided, Residual or Total Bladder Volume. <i>Journal of Urology</i> , 1986, 135, 737-740.	0.2	28
6	3-Year Followup of Urinary Symptoms after Transurethral Resection of the Prostate. <i>Journal of Urology</i> , 1986, 136, 613-615.	0.2	227
7	Detrusor properties related to prostatism. <i>Neurourology and Urodynamics</i> , 1986, 5, 435-447.	0.8	58
8	Identification of the Poor Risk Patient with "Prostatism" and Detrusor Failure. <i>British Journal of Urology</i> , 1986, 58, 290-295.	0.1	52
9	Some Clinical Aspects of Uroflowmetry in Elderly Males: A Population Survey. <i>Scandinavian Journal of Urology and Nephrology</i> , 1986, 20, 93-99.	1.4	61
10	A Population-Based Study of Prostatectomy: Outcomes Associated with Differing Surgical Approaches. <i>Journal of Urology</i> , 1987, 137, 1184-1188.	0.2	123
11	Use of an α_1 -Blocker, YM-12617, in Micturition Difficulty. <i>Urologia Internationalis</i> , 1987, 42, 280-284.	0.6	46
12	Coping with regional variations: The case of surgery in Denmark. <i>International Journal of Health Planning and Management</i> , 1987, 2, 253-264.	0.7	5
13	Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study. <i>British Journal of Urology</i> , 1987, 60, 136-142.	0.1	240
14	Bladder Instability and Denervation in Patients with Bladder Outflow Obstruction. <i>British Journal of Urology</i> , 1987, 60, 519-522.	0.1	173
15	Relationship between Detrusor Function and Residual Urine in Men undergoing Prostatectomy. <i>British Journal of Urology</i> , 1987, 60, 560-566.	0.1	43
16	Prostatectomy or Conservative Management in the Treatment of Benign Prostatic Hypertrophy?. <i>British Journal of Urology</i> , 1988, 61, 432-434.	0.1	33
17	Diagnosis and grading of outflow obstruction. <i>Urology</i> , 1988, 32, 72-77.	0.5	12
18	Phenoxybenzamine in Benign Prostatic Obstruction-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1988, 260, 2220.	3.8	0

#	ARTICLE	IF	CITATIONS
19	Chorionic Villus Sampling. JAMA - Journal of the American Medical Association, 1988, 260, 2220.	3.8	1
20	Watchful Waiting vs Immediate Transurethral Resection for Symptomatic Prostatism. JAMA - Journal of the American Medical Association, 1988, 259, 3010.	3.8	205
21	Symptom Status and Quality of Life Following Prostatectomy. JAMA - Journal of the American Medical Association, 1988, 259, 3018.	3.8	306
22	Symptom Severity and Patients' Values in the Decision to Perform a Transurethral Resection of the Prostate. Medical Decision Making, 1988, 8, 1-8.	1.2	35
23	Decreased Bone Density and Thyroxine-Reply. JAMA - Journal of the American Medical Association, 1988, 260, 2219.	3.8	0
24	Phenoxybenzamine in Benign Prostatic Obstruction. JAMA - Journal of the American Medical Association, 1988, 260, 2220.	3.8	0
25	In vitro fertilisation. BMJ: British Medical Journal, 1988, 296, 1470-1470.	2.4	5
26	Induced ovulation in underweight women. BMJ: British Medical Journal, 1988, 296, 1470-1470.	2.4	0
27	Imaging of the urinary tract. BMJ: British Medical Journal, 1988, 296, 1470-1470.	2.4	3
28	Insulin for the non-insulin dependent?. BMJ: British Medical Journal, 1988, 296, 1469-1470.	2.4	0
29	Urinary retention and the lunisolar cycle: is it a lunatic phenomenon?. BMJ: British Medical Journal, 1989, 299, 1560-1562.	2.4	21
30	Prostatic Urethroplasty Results at the Royal Postgraduate Medical School. Seminars in Interventional Radiology, 1989, 6, 65-71.	0.3	3
31	Characterisation of Human Prostatic Adrenoceptors using Pharmacology Receptor Binding and Localisation. British Journal of Urology, 1989, 63, 487-496.	0.1	134
32	Clinical evaluation of routine urodynamic investigations in prostatism. Neurourology and Urodynamics, 1989, 8, 545-578.	0.8	47
33	Obstructed and unobstructed prostatic obstruction. World Journal of Urology, 1989, 6, 198-203.	1.2	93
34	Natural history of benign prostatic hyperplasia (BPH). Prostate, 1989, 15, 17-22.	1.2	17
35	Surgical management for benign prostatic hyperplasia: Indications, techniques, and results. Prostate, 1989, 15, 79-93.	1.2	14
38	Alpha-adrenoceptor inhibitors in the treatment of benign prostatic hyperplasia. American Journal of Medicine, 1989, 87, S26-S30.	0.6	16

#	ARTICLE	IF	CITATIONS
39	Late renal failure due to prostatic outflow obstruction: a preventable disease.. BMJ: British Medical Journal, 1989, 298, 156-159.	2.4	73
40	Controversies About Indications for Transurethral Resection of the Prostate. Journal of Urology, 1989, 141, 475-481.	0.2	140
41	Benign prostatic hyperplasia: the best treatment.. BMJ: British Medical Journal, 1989, 299, 215-216.	2.4	38
42	Benign prostatic hypertrophy: A view from family practice.. Family Systems Medicine, 1990, 8, 365-370.	0.2	2
44	Alternatives to Prostatectomy. British Journal of Urology, 1990, 65, 313-316.	0.1	26
45	The Dangers of a Long Urological Waiting List. British Journal of Urology, 1990, 65, 433-440.	0.1	20
46	Benign prostatic hyperplasia and its treatment. Journal of General Internal Medicine, 1990, 5, 153-165.	1.3	28
47	The treatment of benign prostatic hyperplasia: a prospective, randomized clinical trial to be conducted by the American Urological Association. World Journal of Urology, 1990, 8, 218-223.	1.2	2
48	Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate, 1990, 16, 253-261.	1.2	115
49	Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate, 1990, 17, 1-7.	1.2	108
50	Critical evaluation of transurethral resection and incision of the prostate. Prostate, 1990, 17, 27-38.	1.2	30
51	Medical outcomes research and benign prostatic hyperplasia. Prostate, 1990, 17, 61-74.	1.2	68
52	Prostate Surgery. Clinics in Geriatric Medicine, 1990, 6, 609-631.	1.0	1
53	Irreversible renal failure in men with outflow obstruction: is it a preventable disease?. Postgraduate Medical Journal, 1990, 66, 996-999.	0.9	8
54	Alfuzosin for benign prostatic hypertrophy. Lancet, The, 1991, 338, 947.	6.3	4
55	Endocrine treatment of benign prostatic hypertrophy: Current concepts. Urology, 1991, 37, 1-16.	0.5	12
56	Natural history of benign prostatic hypertrophy and risk of prostatectomy. Urology, 1991, 38, 4-8.	0.5	151
57	Prostates, Pates, and Pimples: The Potential Medical Uses of Steroid 5 α -Reductase Inhibitors. Endocrinology and Metabolism Clinics of North America, 1991, 20, 893-909.	1.2	21

#	ARTICLE	IF	CITATIONS
58	Benign Prostatic Hyperplasia: Symptoms and Objective Interpretation. <i>European Urology</i> , 1991, 20, 36-40.	0.9	12
59	Benign Prostatic Hyperplasia: Surgical versus Nonsurgical Treatment. <i>European Urology</i> , 1991, 20, 59-62.	0.9	2
60	The Natural History and Course of Untreated Benign Prostatic Hyperplasia. <i>European Urology</i> , 1991, 20, 22-26.	0.9	17
61	Transurethral hyperthermia for benign prostatic hypertrophy. <i>World Journal of Urology</i> , 1991, 9, 2-6.	1.2	25
62	Heat treatment for severe, symptomatic prostatic outflow obstruction. <i>World Journal of Urology</i> , 1991, 9, 7.	1.2	9
63	Balloon dilatation of the prostatic urethra ? should it have a place in the urologist's armamentarium?. <i>World Journal of Urology</i> , 1991, 9, 32.	1.2	2
64	Alpha-adrenoceptor blockers in the treatment of benign prostatic hyperplasia. <i>World Journal of Urology</i> , 1991, 9, 36.	1.2	14
65	Epidemiology of Prostatic Disorders in the City of Barcelona. <i>International Journal of Epidemiology</i> , 1992, 21, 959-965.	0.9	12
66	Assessing Symptom Improvement After Elective Prostatectomy for Benign Prostatic Hypertrophy. <i>Archives of Internal Medicine</i> , 1992, 152, 1507.	4.3	7
67	Review of current and future approaches to the management of benign prostatic hyperplasia.. <i>Postgraduate Medical Journal</i> , 1992, 68, 702-706.	0.9	4
68	Reprocessing data to form QALYs.. <i>BMJ: British Medical Journal</i> , 1992, 305, 87-90.	2.4	44
69	The Role of Urodynamic Investigation in the Assessment of Benign Prostatic Hypertrophy. <i>Journal of Urology</i> , 1992, 148, 1133-1136.	0.2	49
70	Benign Prostatic Hyperplasia: Antecedents and Natural History. <i>Epidemiologic Reviews</i> , 1992, 14, 131-153.	1.3	164
71	Comparison of the Cost-Effectiveness of Various Therapies for Common Prostatic Disorders. <i>Pharmacoeconomics</i> , 1992, 1, 357-369.	1.7	9
72	Diagnostic Parameters. <i>Urologia</i> , 1992, 59, 21-25.	0.3	1
73	Benign prostatic hyperplasia: pathogenesis and the role of medical management. <i>Geriatric Nephrology and Urology</i> , 1992, 2, 1-23.	0.4	3
74	A 12â€­Week Placeboâ€­controlled Doubleâ€­blind Study of Prazosin in the Treatment of Prostatic Obstruction due to Benign Prostatic Hyperplasia. <i>British Journal of Urology</i> , 1992, 70, 285-294.	0.1	43
75	Prospective urodynamic evaluation of the efficacy of prostatic balloon dilatation. <i>Neurourology and Urodynamics</i> , 1992, 11, 483-495.	0.8	8

#	ARTICLE	IF	CITATIONS
76	Panel IX: Alternatives to surgery for benign prostatic hyperplasia. <i>Cancer</i> , 1992, 70, 374-378.	2.0	7
77	A Study of Benign Prostatic Hyperplasia—A Challenge to British Urology. <i>British Journal of Urology</i> , 1993, 71, 38-42.	0.1	33
78	Longitudinal Observations on Normal and Abnormal Voiding in Men Over the Age of 50 Years. <i>British Journal of Urology</i> , 1993, 72, 413-420.	0.1	15
79	Long-Term Treatment of Benign Prostatic Hyperplasia with Alfuzosin: a 12-18 Month Assessment. <i>British Journal of Urology</i> , 1993, 72, 615-620.	0.1	39
80	Comparative Study of Selective α_1 -Adrenoceptor Blockade versus Surgery in the Treatment of Prostatic Obstruction. <i>British Journal of Urology</i> , 1993, 72, 822-825.	0.1	15
81	Alpha-Blocker Treatment with Alfuzosin in Symptomatic Benign Prostatic Hyperplasia: Comparative Study with Prazosin. <i>British Journal of Urology</i> , 1993, 72, 922-927.	0.1	53
82	Immunological similarity between the 170 kD amoebic adherence glycoprotein and human β_2 integrins. <i>Lancet</i> , The, 1993, 341, 17-19.	6.3	38
83	Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. <i>Lancet</i> , The, 1993, 341, 14-17.	6.3	139
84	Medical therapy for benign prostatic hyperplasia. <i>Urology</i> , 1993, 42, 483-501.	0.5	74
85	Transurethral Incision of the Prostate: An Objective and Subjective Evaluation of Long-Term Efficacy. <i>Journal of Urology</i> , 1993, 150, 1615-1621.	0.2	69
86	Relationship of Symptoms of Prostatism to Commonly Used Physiological and Anatomical Measures of the Severity of Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1993, 150, 351-358.	0.2	402
87	Clinical Applications of α_1 -Receptor Blockade: Terazosin in the Management of Hypertension. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 866-899.	1.0	2
88	(TURF) Transurethral Radiofrequency Heating for Benign Prostatic Hyperplasia at Various Temperatures with Thermex II [®] : Clinical Experience. <i>European Urology</i> , 1993, 23, 302-306.	0.9	13
89	Follow-Up of a Cohort of Men with Untreated Benign Prostatic Hyperplasia. <i>European Urology</i> , 1993, 24, 313-318.	0.9	31
90	Who Needs a Prostatectomy? Review of a Waiting List. <i>British Journal of Urology</i> , 1993, 72, 314-317.	0.1	11
91	The Natural History of Benign Prostatic Hyperplasia: Implications for Patient Care and Clinical Trial Design. <i>European Urology</i> , 1994, 25, 10-14.	0.9	3
92	Use of a 7-Day Diary for Urinary Symptom Recording. <i>European Urology</i> , 1994, 26, 227-232.	0.9	8
93	Finasteride. <i>New England Journal of Medicine</i> , 1994, 330, 120-125.	13.9	267

#	ARTICLE	IF	CITATIONS
94	Evaluation and results of treatments for prostatism. Urological Research, 1994, 22, 61-66.	1.5	26
95	Natural course of human benign prostatic hyperplasia with relation to urinary disturbance. Prostate, 1994, 24, 279-284.	1.2	20
96	Subjective and objective evaluation of patients with prostatism and infravesical obstruction treated with both intraprostatic spiral and transurethral prostatectomy. Neurourology and Urodynamics, 1994, 13, 13-19.	0.8	8
97	Critical review of the diagnosis of prostatic obstruction. Neurourology and Urodynamics, 1994, 13, 201-217.	0.8	46
98	Update evaluation of benign prostatic hyperplasia: when should we offer prostatectomy?. British Journal of Urology, 1994, 74, 566-571.	0.1	7
99	A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. British Journal of Urology, 1994, 74, 50-56.	0.1	129
100	Endocrine therapies for symptomatic benign prostatic hyperplasia. Urology, 1994, 43, 7-16.	0.5	16
101	Tamsulosin, a selective α_1 -adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic obstruction™ (symptomatic BPH). British Journal of Urology, 1995, 76, 325-336.	0.1	229
102	Benign Prostatic Hyperplasia – Medical and Minimally Invasive Treatment Options. New England Journal of Medicine, 1995, 332, 99-110.	13.9	209
105	Prostate disease: management options for the primary healthcare team. Report of a working party of the British Prostate Group. Postgraduate Medical Journal, 1995, 71, 136-142.	0.9	9
106	Current treatment of BPH. Biomedicine and Pharmacotherapy, 1995, 49, 332-338.	2.5	9
107	Natural history of benign prostatic hyperplasia: Appropriate case definition and estimation of its prevalence in the community. Urology, 1995, 46, 34-40.	0.5	97
108	α_1 -Blockers vs 5 α -Reductase Inhibitors in Benign Prostatic Hyperplasia. Drugs and Aging, 1995, 6, 388-396.	1.3	12
109	Benign prostatic hyperplasia. Disease-a-Month, 1995, 41, 437-497.	0.4	11
110	Visual Laser Ablation of the Prostate: A Viable Alternative to Transurethral Resection of the Prostate. Mayo Clinic Proceedings, 1995, 70, 97-98.	1.4	2
111	Reasons for the Weak Correlation Between Prostate Volume and Urethral Resistance Parameters in Patients With Prostatism. Journal of Urology, 1995, 153, 689-693.	0.2	65
112	Dependence of Male Voiding Efficiency on Age, Bladder Contractility and Urethral Resistance: Development of a Voiding Efficiency Nomogram. Journal of Urology, 1995, 154, 190-194.	0.2	22
113	Natural History of Prostatism: Longitudinal Changes in Voiding Symptoms in Community Dwelling Men. Journal of Urology, 1996, 155, 595-600.	0.2	186

#	ARTICLE	IF	CITATIONS
114	Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. <i>Urology</i> , 1996, 48, 12-20.	0.5	112
115	The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. <i>Urology</i> , 1996, 47, 169-178.	0.5	36
116	Transurethral Ultrasound-Guided Laser-Induced Prostatectomy: A Critical Evaluation. <i>Journal of Endourology</i> , 1996, 10, 463-467.	1.1	2
117	Three-Year Follow-Up of a Community-Based Cohort of Men with Untreated Benign Prostatic Hyperplasia. <i>European Urology</i> , 1996, 30, 11-17.	0.9	30
118	Long-term drug treatment of benign prostatic hyperplasia – results of a prospective 3-year multicenter study using Sabal extract IDS 89. <i>Phytomedicine</i> , 1996, 3, 105-111.	2.3	13
119	5 α -reductase inhibitors/finasteride. <i>Prostate</i> , 1996, 29, 82-87.	1.2	22
120	Variability of post-void residual urine volume in the elderly. <i>Urological Research</i> , 1996, 24, 23-26.	1.5	73
121	Prostates and profits: The social construction of benign prostatic hyperplasia in American men. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 1996, 17, 1-22.	0.6	8
122	Saw Palmetto Berry in the Treatment of Benign Prostatic Hyperplasia. <i>Clinical Research and Regulatory Affairs</i> , 1997, 14, 53-66.	2.1	2
123	Rapid Approximation of Confidence Intervals for Markov Process Decision Models: Applications in Decision Support Systems. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 1997, 4, 301-312.	2.2	9
124	MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA. <i>Annual Review of Medicine</i> , 1997, 48, 177-189.	5.0	26
125	The Natural History of Patients With Benign Prostatic Hyperplasia as Diagnosed by North American Urologists. <i>Journal of Urology</i> , 1997, 157, 10-15.	0.2	168
126	Natural History of Prostatism: Risk Factors for Acute Urinary Retention. <i>Journal of Urology</i> , 1997, 158, 481-487.	0.2	589
127	Benign Prostatic Hyperplasia. <i>Drugs and Aging</i> , 1997, 10, 349-366.	1.3	59
129	Management of Urinary Incontinence in the Elderly. <i>Gerontology</i> , 1997, 43, 151-157.	1.4	16
130	Epidemiology and Natural History of Benign Prostatic Hyperplasia. <i>International Journal of Urology</i> , 1997, 4, 233-246.	0.5	14
131	Prevalence of lower urinary tract symptoms in Finnish men: a population-based study. <i>BJU International</i> , 1998, 81, 364-369.	1.3	62
132	Prostate cancer: how aware is the public?. <i>BJU International</i> , 1998, 82, 43-48.	1.3	32

#	ARTICLE	IF	CITATIONS
133	TRANSURETHRAL MICROWAVE THERMOTHERAPY FOR BENIGN PROSTATIC HYPERPLASIA: CLINICAL OUTCOME AFTER 4 YEARS. <i>Journal of Urology</i> , 1998, 159, 459-464.	0.2	43
134	Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. I. symptoms and urodynamics. <i>Urology</i> , 1998, 51, 62-72.	0.5	12
135	Population-based studies of the epidemiology of benign prostatic hyperplasia. <i>BJU International</i> , 1998, 82, 34-43.	1.3	39
136	Diseases of the prostate. <i>Reviews in Clinical Gerontology</i> , 1998, 8, 15-22.	0.5	0
137	Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. <i>Urology</i> , 1999, 53, 314-316.	0.5	46
138	Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. <i>Urology</i> , 1999, 53, 1090-1098.	0.5	40
139	THE CHIMPANZEE AS A MODEL OF HUMAN BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 1999, 162, 1454-1461.	0.2	54
140	URINARY INCONTINENCE IN THE OLDER MAN. <i>Medical Clinics of North America</i> , 1999, 83, 1247-1266.	1.1	18
141	INCIDENCE RATES AND RISK FACTORS FOR ACUTE URINARY RETENTION: THE HEALTH PROFESSIONALS FOLLOWUP STUDY. <i>Journal of Urology</i> , 1999, 162, 376-382.	0.2	157
142	Management of Lower Urinary Tract Symptoms in Men. <i>Australasian Journal on Ageing</i> , 2000, 19, 2-10.	0.4	0
143	Epidemiology and classification of urinary incontinence. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2000, 14, 183-205.	1.4	73
144	Tamsulosin for the Treatment of Benign Prostatic Hypertrophy. <i>Annals of Pharmacotherapy</i> , 2000, 34, 188-199.	0.9	39
145	Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas. <i>Urology</i> , 2000, 56, 9-18.	0.5	7
146	The natural history of benign prostatic hyperplasia: what have we learned in the last decade?. <i>Urology</i> , 2000, 56, 3-6.	0.5	127
147	5 α -reductase inhibitors. <i>Advances in Protein Chemistry</i> , 2001, 56, 143-180.	4.4	5
148	Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. <i>Urology</i> , 2001, 58, 210-216.	0.5	113
149	Quality-of-Life Assessment in Patients with Benign Prostatic Hyperplasia. <i>Pharmacoeconomics</i> , 2001, 19, 1079-1090.	1.7	19
150	Do Alpha-Blockers Prevent the Occurrence of Acute Urinary Retention?. <i>European Urology</i> , 2001, 39, 13-18.	0.9	26

#	ARTICLE	IF	CITATIONS
151	A pilot study for a randomized controlled trial comparing the efficacy, safety and cost-effectiveness of surgical treatments of the prostate. <i>BJU International</i> , 2001, 83, 249-253.	1.3	8
152	Minimally invasive non-laser thermal techniques for prostatectomy: a systematic review. <i>BJU International</i> , 2001, 86, 977-988.	1.3	10
153	Prostate volume and prostate-specific antigen in the absence of prostate cancer: A review of the relationship and prediction of long-term outcomes. <i>Prostate</i> , 2001, 49, 208-212.	1.2	30
154	The Impact of Benign Prostatic Hyperplasia Surgery on Patients' Quality of Life. <i>Urologia Internationalis</i> , 2002, 68, 32-37.	0.6	6
155	Clinical Characteristics of α -Blocker Responders in Men with Benign Prostatic Hyperplasia. <i>Urologia Internationalis</i> , 2002, 68, 237-242.	0.6	7
156	Benign Prostatic Hypertrophy. <i>Physician and Sportsmedicine</i> , 2002, 30, 41-47.	1.0	0
157	Effects of Cyclic Stretch On Prostatic Cells in Culture. <i>Journal of Urology</i> , 2002, 168, 2291-2295.	0.2	8
158	The Urologist View of BPH Progression: Results of an International Survey. <i>European Urology</i> , 2002, 41, 490-496.	0.9	29
159	Medical therapy for benign prostatic hyperplasia progression. <i>Current Urology Reports</i> , 2002, 3, 269-275.	1.0	15
160	Does digital rectal examination affect uroflowmetry measurements?. <i>Neurourology and Urodynamics</i> , 2003, 22, 138-141.	0.8	1
161	Is the conservative management of chronic retention in men ever justified?. <i>BJU International</i> , 2003, 92, 581-583.	1.3	33
162	Drug Treatments for Lower Urinary Tract Symptoms Secondary to Bladder Outflow Obstruction. <i>Drugs</i> , 2003, 63, 1947-1962.	4.9	20
163	Natural history of lower urinary tract symptoms in men—result of a longitudinal community-based study in Japan. <i>Urology</i> , 2003, 61, 956-960.	0.5	30
164	Identifying Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) at Risk for Progression. <i>European Urology Supplements</i> , 2003, 2, 6-12.	0.1	19
165	Hipertrofia prostática benigna. <i>Medicine</i> , 2003, 8, 6033-6045.	0.0	4
166	Diseases of the prostate. <i>Reviews in Clinical Gerontology</i> , 2004, 14, 119-128.	0.5	0
167	Guideline for the primary care management of male lower urinary tract symptoms. <i>BJU International</i> , 2004, 93, 985-990.	1.3	80
168	Acute Urinary Retention: a review of the aetiology and management. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, 32-37.	2.0	49

#	ARTICLE	IF	CITATIONS
169	The Link Between LUTS and ED: Clinical and Basic Science Evidence. Journal of Andrology, 2004, 25, 470-478.	2.0	35
170	Benign prostatic hyperplasia progression and its impact on treatment. Current Opinion in Urology, 2004, 14, 45-50.	0.9	16
171	Acute urinary retention: what is the impact on patients' quality of life?. BJU International, 2005, 95, 72-76.	1.3	57
172	The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU International, 2005, 96, 1301-1306.	1.3	93
173	The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated detrusor underactivity. BJU International, 2005, 96, 1295-1300.	1.3	55
174	Do Prostatic Infarction, Prostatic Inflammation and Prostate Morphology Play a Role in Acute Urinary Retention?. European Urology, 2005, 48, 277-284.	0.9	45
175	Transurethral prostatectomy. British Journal of Surgery, 2005, 81, 484-485.	0.1	7
176	Loss to Follow-Up in a Longitudinal Study on Urogenital Tract Symptoms in Dutch Older Men. Urologia Internationalis, 2005, 75, 30-37.	0.6	14
177	A POPULATION BASED STUDY OF INCIDENCE AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AMONG RESIDENTS OF OLMSTED COUNTY, MINNESOTA: 1987 TO 1997. Journal of Urology, 2005, 173, 2048-2053.	0.2	52
178	Noninvasive Methods of Diagnosing Bladder Outlet Obstruction in Men. Part 1: Nonurodynamic Approach. Journal of Urology, 2006, 176, 22-28.	0.2	75
179	First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?. World Journal of Urology, 2006, 24, 360-366.	1.2	15
180	Acute urinary retention: Who is at risk and how best to manage it?. Current Prostate Reports, 2006, 4, 25-32.	0.1	0
181	Acute urinary retention: Who is at risk and how best to manage it?. Current Urology Reports, 2006, 7, 252-259.	1.0	1
182	Inhibitors of 5 α -Reductase in the Treatment of Benign Prostatic Hyperplasia. Current Pharmaceutical Design, 2006, 12, 775-783.	0.9	50
183	Medical treatment of benign prostatic hyperplasia. Postgraduate Medical Journal, 2007, 83, 73-78.	0.9	5
185	Benign Prostatic Hyperplasia and Related Entities. , 2007, , 479-521.		3
186	The urodynamic evaluation of lower urinary tract symptoms in men. Current Bladder Dysfunction Reports, 2008, 3, 49-57.	0.2	4
187	The role of botulinum toxin a in the management of lower urinary tract symptoms. Current Prostate Reports, 2008, 6, 117-122.	0.1	0

#	ARTICLE	IF	CITATIONS
188	A 60-year-old man with lower urinary tract symptoms. <i>Trends in Urology Gynaecology & Sexual Health</i> , 2008, 13, 28-31.	0.1	0
189	Medical management of lower urinary tract symptoms in men: current treatment and future approaches. <i>Nature Reviews Urology</i> , 2008, 5, 211-219.	1.4	19
190	Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. <i>Clinical Interventions in Aging</i> , 2009, 4, 251.	1.3	49
191	Diseases of the prostate. <i>Reviews in Clinical Gerontology</i> , 2010, 20, 10-19.	0.5	3
192	Effect of finasteride on serum prostate-specific antigen (PSA) and on prostate of hamster <i>Mesocricetus auratus</i> (hMa). <i>Acta Cirurgica Brasileira</i> , 2010, 25, 47-54.	0.3	2
193	The Scientific Basis of Urology. , 0, , .		18
194	The Diagnostic Efficacy of 3-Dimensional Ultrasound Estimated Bladder Weight Corrected for Body Surface Area as an Alternative Nonurodynamic Parameter of Bladder Outlet Obstruction. <i>Journal of Urology</i> , 2011, 185, 964-969.	0.2	11
195	Hiperplasia benigna de próstata. <i>Medicine</i> , 2011, 10, 5628-5641.	0.0	0
196	Various treatment options for benign prostatic hyperplasia: A current update. <i>Journal of Mid-Life Health</i> , 2012, 3, 10.	0.4	35
197	Monthly Variation in Acute Urinary Retention Incidence Among Patients With Benign Prostatic Enlargement in Taiwan. <i>Journal of Andrology</i> , 2012, 33, 1239-1244.	2.0	5
198	Noninvasive Methods to Evaluate Bladder Obstruction in Men. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 4-9.	0.7	5
199	Non-Invasive Clinical Parameters for the Prediction of Urodynamic Bladder Outlet Obstruction: Analysis Using Causal Bayesian Networks. <i>PLoS ONE</i> , 2014, 9, e113131.	1.1	14
201	Solving the benign prostatic hyperplasia puzzle. <i>Asian Journal of Urology</i> , 2016, 3, 6-9.	0.5	14
203	Cranberry fruit powder (Flowensâ,,ç) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study. <i>World Journal of Urology</i> , 2016, 34, 419-424.	1.2	18
204	Pathophysiology of clinical benign prostatic hyperplasia. <i>Asian Journal of Urology</i> , 2017, 4, 152-157.	0.5	44
205	A novel algorithm for the non-invasive detection of bladder outlet obstruction in men with lower urinary tract symptoms. <i>Arab Journal of Urology Arab Association of Urology</i> , 2017, 15, 153-158.	0.7	7
206	Benign prostatic hyperplasia –“ medicamentous treatment. <i>Medicina</i> , 2017, 53, 273-284.	0.0	0
207	Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia. <i>Singapore Medical Journal</i> , 2017, 58, 473-480.	0.3	9

#	ARTICLE	IF	CITATIONS
208	Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong. <i>Frontiers in Pharmacology</i> , 2018, 9, 1078.	1.6	3
209	Treatment options for benign prostate enlargement. <i>Journal of Prescribing Practice</i> , 2019, 1, 130-138.	0.1	1
212	Non-Invasive Predictors of Response to Tamsulosin for Benign Prostatic Obstruction. <i>Cureus</i> , 2021, 13, e13341.	0.2	0
213	Lower urinary tract symptoms: initial management in men. <i>The Prescriber</i> , 2021, 32, 13-18.	0.1	0
214	Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part II. <i>Uro</i> , 2021, 1, 139-154.	0.3	3
215	Pharmacological Treatment of Benign Prostatic Hypertrophy. <i>Clinical Practice in Urology</i> , 1984, , 135-152.	0.2	1
216	Basic Considerations. , 1986, , 197-233.		1
217	Obstructive and Functional Abnormalities I. , 1986, , 235-275.		6
218	The Clinical Contribution of Urodynamics. <i>Clinical Practice in Urology</i> , 1983, , 118-174.	0.2	11
219	Natural History of Benign Prostatic Hypertrophy. , 1983, , 5-9.		47
220	Prostatectomy. , 1983, , 35-44.		5
221	Natural History of Benign Prostatic Hyperplasia. , 1993, , 1-12.		2
222	Development of Benign Prostatic Hyperplasia. , 1992, , 1-13.		7
224	EPIDEMIOLOGY AND NATURAL HISTORY OF BENIGN PROSTATIC HYPERPLASIA. <i>Urologic Clinics of North America</i> , 1995, 22, 247-261.	0.8	50
225	UROFLOWMETRY AND URODYNAMICS. <i>Urologic Clinics of North America</i> , 1995, 22, 309-320.	0.8	17
226	ASSESSING TREATMENT RESULTS IN BENIGN PROSTATIC HYPERPLASIA. <i>Urologic Clinics of North America</i> , 1995, 22, 345-355.	0.8	9
227	Epidemiology and Natural History of Benign Prostatic Hyperplasia. <i>Urologic Clinics of North America</i> , 1990, 17, 495-507.	0.8	194
228	Clinical Manifestations of Benign Prostatic Hyperplasia and Indications for Therapeutic Intervention. <i>Urologic Clinics of North America</i> , 1990, 17, 509-516.	0.8	81

#	ARTICLE	IF	CITATIONS
229	Alpha-Adrenergic Blockers for the Treatment of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 1990, 17, 641-649.	0.8	87
230	Evaluation of the Causes and Severity of Geriatric Incontinence. Urologic Clinics of North America, 1991, 18, 243-256.	0.8	28
231	Dependence of Male Voiding Efficiency on Age, Bladder Contractility and Urethral Resistance. Journal of Urology, 1995, 154, 190-194.	0.2	13
232	Natural History of Prostatism. Journal of Urology, 1997, , 481-487.	0.2	30
233	Limitations of Epidemiologically Based Needs Assessment. Medical Care, 1997, 35, 669-685.	1.1	21
234	Controversies in Management: Alternatives are still unproved. BMJ: British Medical Journal, 1994, 309, 717-718.	2.4	3
235	Fortnightly Review: Managing lower urinary tract symptoms in older men. BMJ: British Medical Journal, 1995, 310, 1113-1117.	2.4	33
236	Long-Term Aspects of Medical Treatment of BPH. European Urology, 2001, 40, 8-12.	0.9	27
237	Update on the use of dutasteride in the management of benign prostatic hypertrophy. Clinical Interventions in Aging, 2007, 2, 99-104.	1.3	10
239	Clinical Implications of Residual Urine in Korean Benign Prostatic Hyperplasia (BPH) Patients: A Prognostic Factor for BPH-Related Clinical Events. International Neurourology Journal, 2010, 14, 238-244.	0.5	6
241	Klinische Diagnostik und PCA-Screening. , 2000, , 144-155.		0
243	Effects of Cyclic Stretch On Prostatic Cells in Culture. Journal of Urology, 2002, , 2291-2295.	0.2	0
244	Molekulare Mechanismen von VerÄnderungen und Erkrankungen der Prostata. , 2004, , 296-343.		0
245	Urological Conditions. , 2011, , 433-449.		0
246	Minimally Invasive and Endoscopic Management of Benign Prostatic Hyperplasia. , 2012, , 2655-2694.e8.		14
247	Acute Urinary Retention. , 2014, , 189-193.		0
248	Practical Aspects of the Management of Lower Urinary Tract Obstruction. , 1986, , 299-320.		0
249	Klinischer Wert urodynamischer Untersuchungen. , 1987, , 126-186.		0

#	ARTICLE	IF	CITATIONS
250	Is Pharmacotherapy for Benign Prostatic Hyperplasia an Alternative?. , 1992, , 155-171.		0
251	Hyperthermia or Thermotherapy of Benign Prostatic Hyperplasia: What Is the Difference?. , 1992, , 127-133.		0
252	Transrectal Hyperthermia in Benign Prostatic Hyperplasia. , 1992, , 134-142.		1
253	Benign Prostatic Hypertrophy: Standards and Guidelines. , 1993, , 26-44.		0
254	Assessing Treatment Results for Benign Prostatic Hyperplasia. , 1993, , 45-65.		1
255	The Natural History of Benign Prostatic Hyperplasia. , 1994, , 39-48.		0
256	Transrectal Hyperthermia in Benign Prostatic Hyperplasia. , 1994, , 291-302.		0
257	Introduction: The Clinical Problem. , 1994, , 3-11.		2
258	The Investigation of Benign Prostatic Hyperplasia. , 1994, , 103-112.		0
259	Is Pharmacotherapy a Satisfactory Alternative Treatment for Benign Prostatic Hyperplasia?. , 1994, , 189-212.		0
260	Natural History of Untreated Benign Prostatic Hyperplasia. , 1995, , 132-144.		1
261	Impact of Medical Intervention on the Natural History of Benign Prostatic Hyperplasia. , 1995, , 165-176.		0
262	Impact of Prostatectomy on the Natural History of Benign Prostatic Hyperplasia. , 1995, , 153-164.		0
263	Aetiological Factors in Benign Prostatic Hyperplasia. , 1995, , 107-120.		0
264	Visual Laser Ablation of the Prostate: A Viable Alternative to Transurethral Resection of the Prostate. Mayo Clinic Proceedings, 1995, 70, 97-98.	1.4	0
266	Genitourinary Complications. , 1999, , 448-458.		0
267	Bladder outlet obstruction. , 2019, , 71-128.		1
268	Treatment of Voiding LUTS. , 2020, , 131-167.		0

#	ARTICLE	IF	CITATIONS
271	Pharmacotherapy for benign prostatic hyperplasia. <i>Western Journal of Medicine</i> , 1994, 161, 495-506.	0.3	3
272	Consultation patterns in a community survey of men with benign prostatic hyperplasia. <i>British Journal of General Practice</i> , 1994, 44, 499-502.	0.7	18
273	How long is your waiting list? Experience of a urological waiting list initiative. <i>Journal of the Royal Society of Medicine</i> , 1994, 87, 140-2.	1.1	3
274	Benign prostatic hyperplasia. <i>British Journal of General Practice</i> , 1997, 47, 235-40.	0.7	14
275	Reducing the risk of benign prostatic hyperplasia progression. <i>Reviews in Urology</i> , 2002, 4 Suppl 5, S29-38.	0.9	2
276	The epidemiology of acute urinary retention in benign prostatic hyperplasia. <i>Reviews in Urology</i> , 2001, 3, 187-92.	0.9	21
277	Acute urinary retention: risks and management. <i>Reviews in Urology</i> , 2005, 7 Suppl 4, S31-41.	0.9	13
278	Managing and preventing acute urinary retention. <i>Reviews in Urology</i> , 2005, 7 Suppl 8, S26-33.	0.9	6
279	Long-Term Experience with 5-alpha-Reductase Inhibitors. <i>Reviews in Urology</i> , 2003, 5 Suppl 4, S28-33.	0.9	2
280	Long-Term Experience With 5-alpha-Reductase Inhibitors. <i>Reviews in Urology</i> , 2003, 5 Suppl 5, S22-7.	0.9	2
281	Diagnosis and treatment of benign prostate hyperplasia in Asia. <i>Translational Andrology and Urology</i> , 2015, 4, 478-83.	0.6	6
282	Comparison of the Effects of Tamsulosin, Silodosin, and Alfuzosin on Catheter-Free Trials after Acute Urinary Retention Due to Benign Prostatic Hyperplasia. <i>Urological Science</i> , 2020, 31, 188-193.	0.2	1
283	Effects of cyclic stretch on prostatic cells in culture. <i>Journal of Urology</i> , 2002, 168, 2291-5.	0.2	4
285	How Long is Your Waiting List? Experience of a Urological Waiting List Initiative. <i>Journal of the Royal Society of Medicine</i> , 1994, 87, 140-142.	1.1	3
286	<i>Der geriatrische Patient.</i> , 2022, , 239-250.		0
291	<i>The Geriatric Patient.</i> , 2023, , 219-229.		0
293	Treating LUTS in Men with Benign Prostatic Obstruction: A Review Article. <i>Drugs and Aging</i> , 2023, 40, 815-836.	1.3	2